annual D&A:
$36.49M+$12.09M(+49.55%)Summary
- As of today (June 20, 2025), RXRX annual depreciation & amortization is $36.49 million, with the most recent change of +$12.09 million (+49.55%) on December 31, 2024.
- During the last 3 years, RXRX annual D&A has risen by +$28.09 million (+334.19%).
- RXRX annual D&A is now at all-time high.
Performance
RXRX Depreciation and amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly D&A:
$19.33M+$6.38M(+49.26%)Summary
- As of today (June 20, 2025), RXRX quarterly depreciation & amortization is $19.33 million, with the most recent change of +$6.38 million (+49.26%) on March 31, 2025.
- Over the past year, RXRX quarterly D&A has increased by +$11.95 million (+162.04%).
- RXRX quarterly D&A is now at all-time high.
Performance
RXRX quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM D&A:
$48.45M+$11.95M(+32.76%)Summary
- As of today (June 20, 2025), RXRX TTM depreciation & amortization is $48.45 million, with the most recent change of +$11.95 million (+32.76%) on March 31, 2025.
- Over the past year, RXRX TTM D&A has increased by +$20.40 million (+72.71%).
- RXRX TTM D&A is now at all-time high.
Performance
RXRX TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
RXRX Depreciation and amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +49.5% | +162.0% | +72.7% |
| 3 y3 years | +334.2% | +598.6% | +395.9% |
| 5 y5 years | +1366.2% | +1963.1% | +5070.5% |
RXRX Depreciation and amortization Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +334.2% | at high | +598.6% | at high | +395.9% |
| 5 y | 5-year | at high | +1366.2% | at high | +2155.7% | at high | +5070.5% |
| alltime | all time | at high | +1366.2% | at high | +2155.7% | at high | +5070.5% |
RXRX Depreciation and amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $19.33M(+49.3%) | $48.45M(+32.8%) |
| Dec 2024 | $36.49M(+49.6%) | $12.95M(+79.9%) | $36.49M(+17.4%) |
| Sep 2024 | - | $7.20M(-19.7%) | $31.10M(-1.2%) |
| Jun 2024 | - | $8.97M(+21.6%) | $31.48M(+12.2%) |
| Mar 2024 | - | $7.38M(-2.3%) | $28.05M(+15.0%) |
| Dec 2023 | $24.40M(+107.6%) | $7.55M(-0.3%) | $24.40M(+21.6%) |
| Sep 2023 | - | $7.58M(+36.7%) | $20.06M(+29.7%) |
| Jun 2023 | - | $5.54M(+48.7%) | $15.47M(+21.7%) |
| Mar 2023 | - | $3.73M(+16.0%) | $12.72M(+8.2%) |
| Dec 2022 | $11.76M | $3.21M(+7.5%) | $11.76M(+9.1%) |
| Sep 2022 | - | $2.99M(+7.3%) | $10.78M(+5.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | $2.79M(+0.7%) | $10.22M(+4.7%) |
| Mar 2022 | - | $2.77M(+23.7%) | $9.77M(+16.2%) |
| Dec 2021 | $8.40M(+113.2%) | $2.24M(-8.2%) | $8.40M(+15.2%) |
| Sep 2021 | - | $2.44M(+4.5%) | $7.29M(+27.6%) |
| Jun 2021 | - | $2.33M(+66.3%) | $5.71M(+29.7%) |
| Mar 2021 | - | $1.40M(+24.6%) | $4.41M(+11.8%) |
| Dec 2020 | $3.94M(+58.4%) | - | - |
| Dec 2020 | - | $1.13M(+31.3%) | $3.94M(+39.9%) |
| Sep 2020 | - | $857.00K(-16.3%) | $2.82M(+43.7%) |
| Jun 2020 | - | $1.02M(+9.3%) | $1.96M(+109.3%) |
| Mar 2020 | - | $937.00K | $937.00K |
| Dec 2019 | $2.49M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual depreciation & amortization?
- What is the all time high annual D&A for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual D&A year-on-year change?
- What is Recursion Pharmaceuticals quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly D&A year-on-year change?
- What is Recursion Pharmaceuticals TTM depreciation & amortization?
- What is the all time high TTM D&A for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM D&A year-on-year change?
What is Recursion Pharmaceuticals annual depreciation & amortization?
The current annual D&A of RXRX is $36.49M
What is the all time high annual D&A for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual depreciation & amortization is $36.49M
What is Recursion Pharmaceuticals annual D&A year-on-year change?
Over the past year, RXRX annual depreciation & amortization has changed by +$12.09M (+49.55%)
What is Recursion Pharmaceuticals quarterly depreciation & amortization?
The current quarterly D&A of RXRX is $19.33M
What is the all time high quarterly D&A for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly depreciation & amortization is $19.33M
What is Recursion Pharmaceuticals quarterly D&A year-on-year change?
Over the past year, RXRX quarterly depreciation & amortization has changed by +$11.95M (+162.04%)
What is Recursion Pharmaceuticals TTM depreciation & amortization?
The current TTM D&A of RXRX is $48.45M
What is the all time high TTM D&A for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM depreciation & amortization is $48.45M
What is Recursion Pharmaceuticals TTM D&A year-on-year change?
Over the past year, RXRX TTM depreciation & amortization has changed by +$20.40M (+72.71%)